View DividendTASCOM 관리관리 기준 확인 0/4현재 CEO에 대한 정보가 충분하지 않습니다.주요 정보 최고 경영자n/a총 보상CEO 급여 비율n/aCEO 임기no dataCEO 소유권n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간데이터 없음최근 관리 업데이트YIDOBIO Inc., Annual General Meeting, Mar 23, 2021Feb 20모든 업데이트 표시Recent updatesNew major risk - Market cap size Oct 25TASCOM Co.,Ltd. announced that it has received KRW 1.566576 billion in funding from SV Investment Corporation and other investorsAug 13YIDOBIO Inc. (XKON:A336040) entered into a merger agreement to acquire TASCOM CO.,LTD from Lee Seong-dong and other shareholders for KRW 16.6 billion.Jun 25YIDOBIO Inc., Annual General Meeting, Mar 23, 2021Feb 20YIDOBIO Inc. announced that it has received KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc.Feb 17YIDOBIO Inc. announced that it expects to receive KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc. and other investorsJan 29New 90-day high: ₩25,800 Dec 15New 90-day high: ₩20,750 Nov 13New 90-day high: ₩20,650 Sep 17New 90-day high - ₩20,200 Aug 31New 90-day low - ₩16,500 Jul 27CEOTASCOM 에는 CEO가 없거나 그에 대한 데이터가 없습니다.View Ownership
TASCOM Co.,Ltd. announced that it has received KRW 1.566576 billion in funding from SV Investment Corporation and other investorsAug 13
YIDOBIO Inc. (XKON:A336040) entered into a merger agreement to acquire TASCOM CO.,LTD from Lee Seong-dong and other shareholders for KRW 16.6 billion.Jun 25
YIDOBIO Inc. announced that it has received KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc.Feb 17
YIDOBIO Inc. announced that it expects to receive KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc. and other investorsJan 29